Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CVRX

CVRx Q3 2026 Earnings Date & Estimates

CVRx logo
$1.58 -0.10 (-5.95%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.61 +0.03 (+1.90%)
As of 10/9/2026 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVRx is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from CVRx in Q3 2026

CVRx is expected to post earnings of -$0.49 per share on revenue of $13.93 million. In the same quarter a year earlier CVRx reported -$0.49 per share on revenue of $14.69 million. CVRx last reported on August 6, 2026, posting -$0.53 per share and missing the -$0.5246 consensus estimate. CVRx has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.49
Expected Revenue
$13.93 million
Prior-Year EPS
-$0.49
Prior-Year Revenue
$14.69 million
Expected Revenue Growth
-5.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.53 (Missed by -$0.0054)
Last Quarter Revenue
$15.71 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

CVRx Q3 2026 Earnings FAQ

CVRx (NASDAQ:CVRX) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

CVRx's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect CVRx to post earnings of -$0.49 per share for Q3 2026.

The consensus revenue estimate for CVRx is $13.93 million for Q3 2026.

CVRx Earnings Headlines

CVRx (NASDAQ:CVRX) Upgraded to Hold at Wall Street Zen
October 10 at 1:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104432
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
October 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hagens-berman-national-securities-law-firm-encourages-cvrx-inc-cvrx-investors-with-substantial-losses-to-contact-firm-investigating-potential-securities-fraud-following-59-stock-drop-302896315.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 11 at 1:00 AM  |  Base Camp Trading (Ad)
CVRx, Inc. (NASDAQ:CVRX) Stock Has Average Target Price of $4.30 According to Analysts
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072416
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371349/0/en/cvrx-announces-late-breaking-data-and-new-clinical-evidence-on-barostim-at-the-hfsa-annual-scientific-meeting-2026.html
Lake Street Remains a Hold on CVRx (CVRX)
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CVRX/pressreleases/4756201/lake-street-remains-a-hold-on-cvrx-cvrx/
See More CVRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email.

About CVRx

CVRx (NASDAQ:CVRX) is a medical device company that develops and commercializes neuromodulation technologies for patients with cardiovascular diseases. Founded in 2001 and headquartered in Minneapolis, Minnesota, the company focuses on therapies that use the body’s natural neural pathways to help regulate cardiovascular function.

Its principal product is Barostim, an implantable system designed to treat certain patients with heart failure. The device uses a pulse generator and leads placed near the carotid arteries to electrically activate the baroreflex, a system involved in regulating the heart, blood vessels and nervous system. Barostim is intended for eligible heart failure patients who continue to experience symptoms despite guideline-directed medical therapy and may not be appropriate candidates for, or have not adequately benefited from, other device-based treatments.

CVRx markets its products primarily through cardiovascular specialists and healthcare providers in the United States and select international markets. The company is led by President and Chief Executive Officer Nadim Yared.

View CVRx Profile
Earnings Tools